Diagnostic Accuracy of C-11 Choline and C-11 Acetate for Lymph Node Staging in Patients with Bladder Cancer: a Systematic Review and Meta-analysis

Overview

Journal World J Urol

Specialty Urology

Date 2018 Jan 3

PMID 29294164

Citations 14

Authors

Seong-Jang Kim

Phillip J Koo

Kyoungjune Pak

In-Ju Kim

Keunyoung Kim

Affiliations

Soon will be listed here.

Abstract

Objective: We aimed to assess the diagnostic accuracy of C-11 choline and C-11 acetate positron emission tomography/computed tomography (PET/CT) for lymph node (LN) staging in bladder cancer (BC) patients through a systematic review and meta-analysis.

Methods: The MEDLINE, EMBASE, and Cochrane Library database, from the earliest available date of indexing through June 30, 2017, were searched for studies evaluating the diagnostic performance of C-11 choline and C-11 acetate PET/CT for LN staging in BC. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR-), and constructed summary receiver operating characteristic curves.

Results: Across 10 studies (282 patients), the pooled sensitivity was 0.66 (95% CI 0.54-0.75) without heterogeneity (χ = 12.4, p = 0.19) and a pooled specificity of 0.89 (95% CI 0.76-0.95) with heterogeneity (χ = 29.1, p = 0.00). Likelihood ratio (LR) syntheses gave an overall positive likelihood ratio (LR+) of 5.8 (95% CI 2.7-12.7) and negative likelihood ratio (LR-) of 0.39 (95% CI 0.28-0.53). The pooled diagnostic odds ratio (DOR) was 15 (95% CI 6-38). In meta-regression analysis, the study design (prospective vs retrospective) was the source of the study heterogeneity.

Conclusion: C-11 choline and C-11 acetate PET/CT shows a low sensitivity and moderate specificity for the detection of metastatic LNs in patients with BC. Moreover, heterogeneity among the studies should be considered a limitation. Further large multicenter studies would be necessary to substantiate the diagnostic accuracy of C-11 choline and C-11 acetate PET/CT for this purpose.

Citing Articles

Nuclear Medicine and Molecular Imaging in Urothelial Cancer: Current Status and Future Directions.

McDonald S, Keane K, Gauci R, Hayne D Cancers (Basel). 2025; 17(2).

PMID: 39858014 PMC: 11763387. DOI: 10.3390/cancers17020232.

A narrative review of advances in the management of urothelial cancer: Diagnostics and treatments.

Wu S, Xiong S, Li J, Hong G, Xie Y, Tang Q Bladder (San Franc). 2024; 11(1):e21200003.

PMID: 39308962 PMC: 11413229. DOI: 10.14440/bladder.2024.0003.

Performance of F-FDG PET/MRI and its parameters in staging and neoadjuvant therapy response evaluation in bladder cancer.

Li T, You Q, Zhang S, Li R, Xie S, Li D iScience. 2024; 27(5):109657.

PMID: 38689640 PMC: 11059538. DOI: 10.1016/j.isci.2024.109657.

Vascular Enlargement as a Predictor of Nodal Involvement in Bladder Cancer.

Borgheresi A, Agostini A, Sternardi F, Cesari E, Ventura F, Ottaviani L Diagnostics (Basel). 2023; 13(13).

PMID: 37443621 PMC: 10340831. DOI: 10.3390/diagnostics13132227.

PET Imaging in Bladder Cancer: An Update and Future Direction.

Zhang-Yin J, Girard A, Marchal E, Lebret T, Homo Seban M, Uhl M Pharmaceuticals (Basel). 2023; 16(4).

PMID: 37111363 PMC: 10144644. DOI: 10.3390/ph16040606.

References

Kates A, Herrero P, Dence C, Soto P, Srinivasan M, Delano D . Impact of aging on substrate metabolism by the human heart. J Am Coll Cardiol. 2003; 41(2):293-9. DOI: 10.1016/s0735-1097(02)02714-6. View

Maurer T, Souvatzoglou M, Kubler H, Opercan K, Schmidt S, Herrmann K . Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. Eur Urol. 2011; 61(5):1031-8. DOI: 10.1016/j.eururo.2011.12.009. View

de Jong I, Pruim J, Elsinga P, Jongen M, Mensink H, Vaalburg W . Visualisation of bladder cancer using (11)C-choline PET: first clinical experience. Eur J Nucl Med Mol Imaging. 2002; 29(10):1283-8. DOI: 10.1007/s00259-002-0881-7. View

Swinnen G, Maes A, Pottel H, Vanneste A, Billiet I, Lesage K . FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol. 2009; 57(4):641-7. DOI: 10.1016/j.eururo.2009.05.014. View

Herr H, Dotan Z, Donat S, Bajorin D . Defining optimal therapy for muscle invasive bladder cancer. J Urol. 2007; 177(2):437-43. DOI: 10.1016/j.juro.2006.09.027. View

Oyama N, Miller T, Dehdashti F, Siegel B, Fischer K, Michalski J . 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med. 2003; 44(4):549-55. View

Glas A, Lijmer J, Prins M, Bonsel G, Bossuyt P . The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003; 56(11):1129-35. DOI: 10.1016/s0895-4356(03)00177-x. View

Vind-Kezunovic S, Bouchelouche K, Ipsen P, Hoyer S, Bell C, Jensen J . Detection of Lymph Node Metastasis in Patients with Bladder Cancer using Maximum Standardised Uptake Value and F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Results from a High-volume Centre Including Long-term Follow-up. Eur Urol Focus. 2017; 5(1):90-96. DOI: 10.1016/j.euf.2017.06.005. View

Schiavina R, Borghesi M, Guidi M, Vagnoni V, Zukerman Z, Pultrone C . Perioperative complications and mortality after radical cystectomy when using a standardized reporting methodology. Clin Genitourin Cancer. 2013; 11(2):189-97. DOI: 10.1016/j.clgc.2012.12.003. View

10.

Thompson S . Why sources of heterogeneity in meta-analysis should be investigated. BMJ. 1994; 309(6965):1351-5. PMC: 2541868. DOI: 10.1136/bmj.309.6965.1351. View

11.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

12.

Czernin J, Allen-Auerbach M, Schelbert H . Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med. 2007; 48 Suppl 1:78S-88S. View

13.

Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J . QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155(8):529-36. DOI: 10.7326/0003-4819-155-8-201110180-00009. View

14.

Husband J . Computer tomography and magnetic resonance imaging in the evaluation of bladder cancer. J Belge Radiol. 1995; 78(6):350-5. View

15.

Brusselmans K, De Schrijver E, Verhoeven G, Swinnen J . RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res. 2005; 65(15):6719-25. DOI: 10.1158/0008-5472.CAN-05-0571. View

16.

Graziani T, Ceci F, Lopes F, Chichero J, Castellucci P, Schiavina R . 11C-choline PET/CT for restaging of bladder cancer. Clin Nucl Med. 2014; 40(1):e1-5. DOI: 10.1097/RLU.0000000000000573. View

17.

Boellaard R, Oyen W, Hoekstra C, Hoekstra O, Visser E, Willemsen A . The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008; 35(12):2320-33. DOI: 10.1007/s00259-008-0874-2. View

18.

Ceci F, Bianchi L, Graziani T, Castellucci P, Pultrone C, Eugenio B . 11C-choline PET/CT and bladder cancer: lymph node metastasis assessment with pathological specimens as reference standard. Clin Nucl Med. 2014; 40(2):e124-8. DOI: 10.1097/RLU.0000000000000604. View

19.

Palmieri F, Brunocilla E, Bertaccini A, Guidi M, Pernetti R, Morselli-Labate A . Prognostic value of lymphovascular invasion in bladder cancer in patients treated with radical cystectomy. Anticancer Res. 2010; 30(7):2973-6. View

20.

Golan S, Sopov V, Baniel J, Groshar D . Comparison of 11C-choline with 18F-FDG in positron emission tomography/computerized tomography for staging urothelial carcinoma: a prospective study. J Urol. 2011; 186(2):436-41. DOI: 10.1016/j.juro.2011.03.121. View